Early last week, the FDA approved Biogen’s Alzheimer’s drug Aduhelm on “accelerated” basis. This was a landmark moment for those millions who are suffering from the aging disease and for scientists who have spent decades trying to understand the underlines of the disease and to invent drugs to slow, if not to cure the disease. Though the effectiveness of the Aduhelm is not very significant and the FDA approval is controversial, I think its impact is significant to inspire more researches and more funding to invent drugs to tackle Alzheimer’s. Here are two other companies I am watching closely.
- Annovis Bio, Inc. (ANVS), its drug at phase 2 clinical trials.
- Anavex Life Sciences Corp (AVXL), its drug at phase 3 clinical trials.